The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.
 
Maria Gonzalez
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Thomas Pennington
No Relationships to Disclose
 
Robyn PM Saw
Honoraria - Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis
 
Andrew J. Spillane
No Relationships to Disclose
 
Jonathan Stretch
No Relationships to Disclose
 
Kerwin Frank Shannon
Honoraria - Merck Serono
Consulting or Advisory Role - Merck Serono
 
Sydney Ch'ng
No Relationships to Disclose
 
Omgo E. Nieweg
No Relationships to Disclose
 
Maria Cruzado Rojas
No Relationships to Disclose
 
Monica Osorio
No Relationships to Disclose
 
Robert V Rawson
No Relationships to Disclose
 
Peter M. Ferguson
No Relationships to Disclose
 
Helen Rizos
No Relationships to Disclose
 
Serigne Lo
No Relationships to Disclose
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; NeraCare GmbH; Novartis
Research Funding - National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche